-
Product Insights
NewRectal Cancer – Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...
-
Product Insights
NewTyrosine Protein Phosphatase Non Receptor Type 11 – Drugs In Development, 2024
The Tyrosine Protein Phosphatase Non Receptor Type 11 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type 11 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Immunology, and Metabolic Disorders which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Multiple Sclerosis, Autoimmune Disorders, and Type...
-
Product Insights
NewRAF Proto Oncogene Serine/Threonine Protein Kinase – Drugs In Development, 2024
The RAF Proto Oncogene Serine/Threonine Protein Kinase pipeline drugs market research report outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Genetic Disorders which include indications of Solid Tumor, Oncology, and Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis). It also reviews key players involved...
-
Product Insights
NewMitogen Activated Protein Kinase 3 – Drugs In Development, 2024
The Mitogen Activated Protein Kinase 3 pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Genetic Disorders, and Cardiovascular which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Psoriasis, Neurofibromatoses Type I (Von Recklinghausen's Disease), and Hypertension. It also reviews...
-
Product Insights
NewMitogen Activated Protein Kinase 1 – Drugs In Development, 2024
The Mitogen Activated Protein Kinase 1 pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Musculoskeletal Disorders, and Dermatology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Psoriasis, Autoimmune Disorders, Osteoarthritis, Ankylosing Spondylitis (Bekhterev's Disease), and Dermatology. It also...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewGTPase KRas – Drugs In Development, 2024
The GTPase KRas pipeline drugs market research report outlays comprehensive information on the GTPase KRas targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Undisclosed, Infectious Disease, and Immunology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Unspecified, Epstein–Barr Virus (HHV-4) Infections, and Unspecified Immunological Disorders. It also reviews key players involved in GTPase KRas...
-
Product Insights
NewSerine/Threonine Protein Kinase ULK1 – Drugs In Development, 2024
The Serine/Threonine Protein Kinase ULK1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase ULK1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Oncology. It also reviews key players involved in Serine/Threonine Protein Kinase ULK1 targeted therapeutics development with respective active and dormant or discontinued...
-
Product Insights
NewSerine/Threonine Protein Kinase B Raf – Drugs In Development, 2024
The Serine/Threonine Protein Kinase B Raf pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase B Raf targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Dermatology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Kabuki Syndrome,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naporafenib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naporafenib in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naporafenib in Metastatic Melanoma Drug Details: Naporafenib (LXH-254) is under development...